Results 161 to 170 of about 15,116 (246)
Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial (OXB‐102/Axo‐Lenti‐PD) in People with Parkinson's Disease
Movement Disorders, EarlyView.Abstract Background
SUNRISE‐PD was a dose‐escalating, phase 1/2 study investigating a second‐generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB‐102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.Simon Rowe, Amy Evans, Saeed Kayhanian, Philip C. Buttery, Robert Morris, Katie Andresen, Laura Sherlock, Samuel Hewitt, Tagore Nakornchai, Marwan Hariz, Kyriacos Mitrophanous, Ludvic Zrinzo, Matthew Appleby, Phil Woodgate, Seema Maru, Patricia Limousin, Christine Girges, Thomas Foltynie, Stephane Palfi, Roger A. Barker +19 morewiley +1 more sourceLevodopa and Melanoma: Practical Recommendations for Parkinson's Disease—International Parkinson and Movement Disorder Society Scientific Issues Committee Viewpoint
Movement Disorders Clinical Practice, EarlyView.Giorgia Sciacca, Inas Elsayed, Santiago Perez‐Lloret, Tiago F. Outeiro, Vivek K. Unni, Jeffery H. Kordower, Daniela Berg, Lorraine V. Kalia, on behalf of the MDS Scientific Issues Committee, Jane Alty, Alexander Balck, Daniela Berg, Per Borghammer, Inas Elsayed, Yue Huang, Walaa Kamel Elsayed, Jeffrey Kordower, Alexander Lehn, Michele Matarazzo, Tiago Mestre, Tiago Outeiro, Gian Pal, Santiago Perez Lloret, Roopa Rajan, Sephira Ryman, Giorgia Sciacca, Per Svenningsson, Lorraine Kalia +27 morewiley +1 more sourceA Gap Analysis of Deep Brain Stimulation for Childhood‐Onset Movement Disorders
Movement Disorders, EarlyView.Abstract Background
Deep brain stimulation (DBS) is an established and increasingly utilized therapy for childhood‐onset movement disorders. However, pediatric DBS poses unique challenges that are not adequately addressed by adult‐derived paradigms. Objective
To identify key gaps in the current use of DBS in childhood‐onset movement disorders and to ...Daniela Munoz‐Chesta, Carolina Gorodetsky, Todd M. Herrington, Angela L. Hewitt, Daniel E. Lumsden, Jennifer O'Malley, Terence Sanger +6 morewiley +1 more sourceChallenges of Pain in Parkinson's Disease: Results from the OCEAN Study
Movement Disorders, EarlyView.Abstract Background
Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective
The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.Kallol Ray Chaudhuri, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Monica M. Kurtis, Alexander Storch, José‐Francisco Rocha, Raquel Costa, Diogo Magalhães, Guillermo Castilla‐Fernández, Helena C. Brigas, Joerg Holenz, Per Odin, on behalf of the OCEAN study group +13 morewiley +1 more sourcePlasma p‐tau217 Versus p‐tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease‐Related Neurostructural Changes and Cognitive Function
Movement Disorders, EarlyView.Abstract Background
Plasma phosphorylated‐tau at threonine‐217 (p‐tau217) and threonine‐181 (p‐tau181) are scalable, minimally invasive biomarkers of Alzheimer's disease (AD) pathology. In Parkinson's disease (PD), AD co‐pathology may contribute to its clinical heterogeneity.Eleonora Fiorenzato, Simone Cauzzo, Giulia Musso, Roberta Biundo, Chiara Ceolin, Chiara Cosma, Carmelo Alessandro Fogliano, Wassilios G. Meissner, Valentina Misenti, Stefania Moz, Maria Laura Nasi, Francesca Vianello, Renzo Manara, Martina Montagnana, Giuseppe Sergi, Angelo Antonini, on behalf of the OPA Working Group +16 morewiley +1 more sourceA Phase 1 Study of Convection‐Enhanced Delivery of Intraputaminal AAV2‐GDNF in Advanced Parkinson's Disease
Movement Disorders, EarlyView.Abstract Background
Parkinson's disease (PD) is a progressive neurodegenerative disorder. Neurotrophic therapeutic approaches have been limited in part by incomplete delivery to the putamen. We developed image‐guided convection‐enhanced delivery with real‐time monitoring to improve intraputaminal distribution of neurotrophic gene therapy. Objectives
To John D. Heiss, Debra J. Ehrlich, Codrin Lungu, Joseph Y. Choi, Gretchen Scott, Irene Dustin, Dima A. Hammoud, Peter Herscovitch, Russell R. Lonser, Kareem A. Zaghloul, Krystof Bankiewicz +10 morewiley +1 more sourceSpatiotemporal Progression Patterns of Striatal Dopamine Depletion and Cerebral Hypoperfusion in Parkinson's Disease
Movement Disorders, EarlyView.Abstract Background
The identification of Parkinson's disease (PD) subtypes is crucial for predicting the disease course and designing personalized therapeutic strategies. Objectives
The aim of the study was to characterize the heterogeneity of the spatiotemporal evolutionary patterns of striatal dopamine depletion and cerebral hypoperfusion in PD ...Yeeun Sun, Youngseok Choi, Chan Wook Park, Han Kyu Na, Hye Sun Lee, Yun Joong Kim, Young H. Sohn, Phil Hyu Lee, Jeyeon Lee, Seok Jong Chung +9 morewiley +1 more sourceMelanopsin‐Mediated Post‐Illumination Pupillary Response in Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder and Parkinson's Disease
Movement Disorders, EarlyView.Abstract Aims
To conduct a case–control study to investigate melanopsin‐mediated post‐illumination pupillary response (PIPR) in patients with Parkinson's disease (PD), video‐polysomnography‐confirmed isolated/idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD), and age‐matched healthy controls (HC). Methods
PIPR was measured at 6 s after Joey W.Y. Chan, Bei Huang, Siyi Gong, Yuhua Yang, Shi Tang, Steven Wai‐ho Chau, Ngan Yin Chan, Tim Man‐ho Li, Yaping Liu, Anne Y.Y. Chan, Karen K.Y. Ma, Shirley X. Li, Joshua Tsoh, Kelvin K.L. Chong, Kathryn A. Roecklein, Vincent C.T. Mok, Yun Kwok Wing +16 morewiley +1 more sourceHyperhomocysteinemia and Vitamin B Deficiency as Potential Aggravating Factors in Huntington's Disease: A Prospective Monocentric Study
Movement Disorders, EarlyView.Abstract Background
Although not confirmed, some studies have suggested that elevated homocysteine levels are common in patients with Huntington's disease (HD). Its clinical relevance remains unclear. Objectives
We aimed to assess vitamin B and homocysteine levels in HD patients and explore the relationships among hyperhomocysteinemia, vitamin B ...Salomé Puisieux, Elise Pourié, Céline Bonnet, Lucie Hopes, Solène Frismand, Myriam Bronner, Virginie Roth, Marion Wandzel, Natacha Sloboda, Laetitia Lambert, Abderrahim Oussalah, Amélia Julien, Irina Rotaru, Rosa‐Maria Guéant‐Rodriguez, Jean Louis Guéant, Carine Bossenmeyer‐Pourié, Mathilde Renaud +16 morewiley +1 more source